The Benevolent Platform™ drives our three revenue streams. Our business model offers multiple routes for revenue generation and value creation.
Established business
End-to-end drug discovery
Drug discovery offerings
- Platform enables novel discoveries throughout the drug discovery process
- Continuing to expand on our industry-leading collaborations
- Validated by collaborations with AstraZeneca and Merck
High value collaborations
Upfront payments + milestones + royalties
Preclinical and clinical development pipeline
Platform generated assets
- Five high potential assets
- Potentially first-in-class or best-in-class assets providing novel therapeutic opportunities
- Progressing assets to significant inflection points
Mid to long-term value creation
Upfront fees + milestones + royalties
New expansion opportunities
Knowledge Exploration Tools
New customisable SaaS products
- Suite of AI products that surface data, perform analysis, and give scientific recommendations
- BenAI-Q and BenAI Research Assistant products enabling enhanced decision making
- Building from our core technologies to develop innovative ways to serve customers and their scientists
Highly scalable, recurring revenue
Fees for setup, platform licences and seats + ongoing support services
LEARN MORE
Reach your full research and development potential.
Speak to our business development team.